Glucose/Sodium Chloride Fresenius Kabi

Glucose/Sodium Chloride Fresenius Kabi is an injectable solution that contains sodium chloride and glucose monohydrate. It is supplied as a sterile intravenous (IV) fluid for infusion, intended for use in clinical settings within the European Union. The product provides both electrolytes and carbohydrate energy to support fluid balance and metabolic needs during medical treatment.

Glucose/Sodium Chloride Fresenius Kabi is used in a variety of clinical situations where fluid, electrolyte, and energy replacement are required.

- Fluid replacement in patients with dehydration or blood loss - Electrolyte replenishment for sodium and chloride deficits - Treatment of hypoglycemia when rapid glucose delivery is needed - Component of parenteral nutrition regimens - Support during surgery or intensive care for maintaining intravascular volume

Adverse reactions to Glucose/Sodium Chloride Fresenius Kabi may vary in frequency and severity.

Common: - Local irritation at the infusion site - Mild nausea or vomiting - Transient hyperglycemia - Mild electrolyte imbalance (e.g., hypernatremia) - Headache - Mild fever

Serious: - Severe hyperglycemia leading to osmotic diuresis - Significant electrolyte disturbances (e.g., severe hypernatremia, hyperchloremic acidosis) - Anaphylactic or severe allergic reaction - Thrombophlebitis or venous thrombosis - Fluid overload with pulmonary edema

When administering Glucose/Sodium Chloride Fresenius Kabi, clinicians should consider several safety factors.

- Assess patient’s fluid status and electrolyte levels before infusion - Monitor blood glucose regularly, especially in diabetic patients - Adjust infusion rate in patients with cardiac or renal impairment to avoid overload - Use aseptic technique to prevent contamination and infection - Verify compatibility with other IV medications before co‑administration - Observe for signs of allergic reaction during and after infusion

Glucose/Sodium Chloride Fresenius Kabi can interact with other therapies, influencing safety and efficacy.

Avoid: - Concurrent administration of high‑dose insulin without glucose monitoring, which may cause severe hypoglycemia - Use with hypertonic saline solutions that could exacerbate hypernatremia - Co‑infusion with medications that precipitate in high‑chloride environments (e.g., certain antibiotics)

Use with caution: - Diuretics that may alter electrolyte balance - Beta‑blockers that can mask hypoglycemia symptoms - Corticosteroids that increase glucose levels - Renal replacement therapies that affect fluid and electrolyte removal